Background & Aims We investigated the real-world effectiveness of sofosbuvir,
ledipasvir/sofosbuvir, and paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD) in treatment …

Background Real‐world data are needed to inform hepatitis C virus (HCV) treatment
decisions. Aim To assess the comparative effectiveness of ledipasvir/sofosbuvir±ribavirin …

Background & Aims The combination of ledipasvir and sofosbuvir has been approved for
treatment of genotype 1 hepatitis C virus (HCV) infection, including an 8-week regimen for …

Abstract Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) provides a needed hepatitis C
virus (HCV) antiviral option for direct‐acting antiviral (DAA)‐experienced patients. We …

Background Interferon-based treatment is not suitable for many patients with hepatitis C
virus (HCV) infection because of contraindications such as psychiatric illness, and a high …

Background & Aims We performed a phase 2 clinical trial to evaluate the efficacy and safety
of ledipasvir and sofosbuvir, with or without ribavirin, in patients infected with hepatitis C …

Background & Aims We evaluated an all-oral regimen comprising the nucleotide
polymerase inhibitor sofosbuvir (SOF) with the NS5A inhibitor ledipasvir (LDV) or the NS5B …

Patients who fail to achieve sustained virological response (SVR) after treatment with
sofosbuvir (SOF) plus ribavirin (RBV) with or without pegylated interferon (Peg‐IFN) do not …

Background Real‐world effectiveness data are needed to inform hepatitis C virus (HCV)
treatment decisions. Aim To assess sustained virological response (SVR) of sofosbuvir …

Background Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients
who have not had a sustained virologic response to prior interferon-based therapy …